Marta Gil-Martín - Publications, H-index & Citations

Marta Gil-Martín

Catalan Institute of Oncology

28H指数

232论文数

5.5K被引数

收录论文 45

发表时间

Primary Radiotherapy Versus Surgery in Early-Stage Endometrial Cancer Among High-Risk Surgical Patients: A Retrospective Comparative Study 高风险手术患者早期子宫内膜癌的一线放疗与手术治疗的回顾性比较研究

Cancers

IF4.4

2026-06-05

OAAI

Lucia Gómez-Lavin Fernández; Sergi Fernández-González; Dina Najjari-Jamal; Lola Marti Cardona; Marc Juarez Lozano; Marc Barahona; Marta Gil Martin; Beatriz Pardo Burdalo; Andrea Slocker Escarpa; Milica Stefanovic; Cristina Gutiérrez Miguelez; Jordi Ponce Sebastià

Early Supportive vs Standard Care in Phase I Cancer Trials: A Randomized Controlled Trial 早期支持性护理与标准护理在I期癌症试验中的比较：一项随机对照试验

Journal of Pain and Symptom Management

IF3.5

2026-02-09

OAAI

Anna Casellas-Grau; Claudia Cruz-Sequeiros; Sílvia Sala-Suñé; Kevin Molina-Mata; Elisabeth Barbero-Biedma; Sílvia Llorens-Torromé; Gala Serrano-Bermúdez; Carmen Cuadra-Amor; Marta Gil-Martín; Ramon Salazar; Francisco Gil

Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort 探讨卵巢癌长期生存者中未满足需求的研究（ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI）：来自西班牙队列的见解

International Journal of Gynecological Cancer

IF4.7

2026-01-07

PREAI

Maria-Pilar Barretina-Ginesta; Ainhoa Madariaga; Marta Gil-Martín; Avinash Ramchandani; Marta Pardo; Ana Beatriz Sanchez-Heras; Cristina Churruca; Eva Maria Guerra-Alia; Caterina Madroñal; Julen Fernandez-Plana; Ana Herrero; Emma Dotor; Carmen Esteban; María Quindós-Varela; Margarita Romeo; Ester Gost; María José Bermejo; Concepción Fernandez-Chacón; Neus Ferrer; Cesar Gomez-Raposo

EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)EO2401多肽免疫疗法联合纳武利尤单抗及/或贝伐珠单抗治疗首次复发的胶质母细胞瘤：EOGBM1-18 / ROSALIE（NCT04116658）研究中的治疗策略优化（I/II期研究）

NEURO-ONCOLOGY

IF13.4

2025-11-01

OAAI

Reardon, David A.; Idbaih, Ahmed; Vieito, Maria; Ghiringhelli, Francois; Stradella, Agostina; Tabatabai, Ghazaleh; Burger, Michael C.; Mildenberger, Iris; Herrlinger, Ulrich; Wen, Patrick Y.; Touat, Mehdi; Wick, Antje; Gonzalez, Macarena; Hervieu, Alice; Gil-Martin, Marta; Renovanz, Mirjam; Gouttefangeas, Cecile; Maia, Ana; Chene, Laurent; Fagerberg, Jan; Rinaudo, Philippe; Wick, Wolfgang

SEOM-GEICO clinical guidelines on endometrial cancer (2025)SEOM-GEICO关于子宫内膜癌的临床指南（2025）

Clinical and Translational Oncology

IF2.5

2025-09-23

OAAI

Sara Pérez Ramírez; Alejandro Pérez Fidalgo; María Pilar Barretina Ginesta; Ana De Juan Ferré; Lorena Fariñas Madrid; Alejandro Gallego Martínez; Fernando Gálvez Montosa; Ainhoa Madariaga; Teresa Martin Gómez; Marta Gil-Martin

Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations 度伐利尤单抗联合卡铂/紫杉醇后序贯度伐利尤单抗治疗子宫内膜癌的一线治疗：DUO-E/GOG-3041/ENGOT-EN10研究中的意向性治疗人群和错配修复缺陷人群的患者报告结局

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

IF4.7

2025-02-01

PREAI

Meyer, Larissa A.; Westin, Shannon N.; Messing, Mark; Hartenbach, Ellen; Carney, Michael; Bradley, William; Sobol, Urszula; Depasquale, Stephen; Agyemang-Prempeh, Kofi; Gil-Martin, Marta; Zagouri, Flora; Bodnar, Lubomir; Palmeiro, Daniela Neves; Wu, Xiaohua; Otero, Marco Antonio Torregroza; Nishikawa, Tadaaki; Kim, Jae-Weon; Donnelly, Conor; Jethoo, Gordhan; Van Nieuwenhuysen, Els

Palbociclib plus letrozole in estrogen receptor-positive advanced/ recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial 帕博西利联合来曲唑在雌激素受体阳性晚期/复发性子宫内膜癌中的应用：双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

gynecologic oncology

IF4.1

2025-01-01

OAAI

Mirza, Mansoor R.; Bjorge, Line; Marme, Frederik; Christense, Rene DePont; Gil-Martin, Marta; Auranen, Annika; Ataseven, Beyhan; Rubio, Maria Jesus; Salutari, Vanda; Luczak, Adam A.; Runnebaum, Ingo B.; Redondo, Andres; Lindemann, Kristina; Trillsc, Fabian; Ginesta, M. Pilar Barretina; Roed, Henrik; Kurtz, Jean-Emmanuel; Petersson, Karen S.; Nyvang, Gitte-Bettina; Sehouli, Jalid

Lessons learned from a pan-cancer exploratory Liquid Biopsy (LB) profiling: the PREICO-LB project

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-01

PREAI

Hierro, C.; Notario, L.; Bergamino, M.; Sabat, P.; Soto-Castillo, J. J.; Calvo, M.; Oliva, M.; Jove, M.; Ruffinelli, J. C.; Mosteiro, M. A.; Ochoa de Olza, M.; Carcereny, E.; Balana, D.; Gonzalez, M. I.; Fina, C.; Gil-Martin, M.; Nadal, E.; Azuara, D.; Lazaro, C.; Martin-Liberal, J.

A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (vol 24, 876, 2024)

BMC CANCER

IF3.4

2024-07-29

OAAI

Leary, Alexandra; Estevez-Garcia, Purificacion; Sabatier, Renaud; Ray-Coquard, Isabelle; Romeo, Margarita; Barretina-Ginesta, Pilar; Gil-Martin, Marta; Garralda, Elena; Bosch-Barrera, Joaquim; Moran, Teresa; Martin-Martorell, Paloma; Nadal, Ernest; Gascon, Pere; Rodon, Jordi; Lizcano, Jose M.; Munoz-Guardiola, Pau; Fierro-Duran, Gemma; Pedros-Gamez, Oriol; Perez-Montoyo, Hector; Yeste-Velasco, Marc; Cortal, Marc; Perez-Campos, Antonio; Alfon, Jose; Domenech, Carles; Perez-Fidalgo, Alejandro; Oaknin, Ana

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

BMC CANCER

IF3.4

2024-07-22

OAAI

Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

ANNALS OF ONCOLOGY

IF65.4

2024-06-01

PREAI

Hsu, C-H.; Dziadziuszko, R.; Gomez Abreo, D. A.; Aksoy, S.; Gil Martin, M.; Roderburg, C.; Yen, C. J.; Arican, A.; Cassier, P.; Im, S-A.; Kim, S-B.; Kudo, T.; Ochsenreither, S.; Sendur, M. A. N.; Yonemori, K.; Rojas, C. I.; Liu, Q.; Keenan, T.; Healy, J.; Kwiatkowski, M.

Targeting CSF1R with BLZ945 results in effective peripheral and tumor immune microenvironment modulation in advanced solid tumors and may be associated with limited efficacy in recurrent non-mesenchymal glioblastoma

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Del Alcazar, Carlos Rodrigo Gil; Xu, Virginia; Lin, Chia-Chi; Gil-Martin, Marta; Naing, Aung; Fan, Liqiong; Yang, Fang; Quinn, David; Wu, Jincheng; Quadt, Cornelia; Mataraza, Jennifer

Phase 1 study of the anti-immunoglobulin-like transcript 4 ( ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non- small cell lung cancer (NSCLC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Cho, Byoung Chul; Hilton, John; Rodriguez, Cristina P.; Bonomi, Marcelo; Siu, Lillian L.; Gil-Martin, Marta; Siddiqi, Shabana; Myer, Nicole M.; Suttner, Leah; Wilson, Douglas; Akala, Omobolaji; Dziadziuszko, Rafal

Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Siu, Lillian L.; Gil-Martin, Marta; Cho, Byoung Chul; Perets, Ruth; Hilton, John; Geva, Ravit; Lugowska, Iwona; Gutierrez, Martin; Bonomi, Marcelo; Dziadziuszko, Rafal; Rasco, Drew; Ben-Ami, Eytan; Rodriguez, Cristina P.; Siddiqi, Shabana; Myer, Nicole; Suttner, Leah; Wilson, Douglas; Akala, Ombololaji O.; de Miguel, Maria

A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Piulats Rodriguez, J. M.; Palacio Vazquez, I.; Alarcon, J. D.; Gatius, S.; Marin Jimenez, J. A.; Gil Martin, M.; Marquez Aragones, A.; Santacana, M.; Manso Sanchez, L. M.; Hernando Polo, S.; Ruiz, N.; Matias-Guiu, X.; Romeo Marin, M.; Navarro Garces, V.; Barbarroja, P.

Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Westin, S. N.; Moore, K. N.; Chon, H. S.; Lee, J. Y.; Pepin, J. Thomes; Sundborg, M.; De la Garza, J.; Nishio, S.; Wang, K.; Mcintyre, K.; Tillmanns, T.; Mejia, F. Contreras; De Melo, A. C.; Klasa-Mazurkiewicz, D.; Papadimitriou, C. A.; Martin, M. Gil; Brasiuniene, B.; Donnelly, C.; Liu, X.; Van Nieuwenhuysen, E.

Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Castillo, J. J. Soto; Rincon, L. Notario; Azuara, D.; Ruffinelli, J. C.; Stradella, A.; Bernal, M. Oliva; Campos, M. Calvo; Jove, M.; Serna, S. Llop; Vazquez, R. Villanueva; Amor, C. Cuadra; Bergamino, M. A.; Vila, E. Teixidor; Gomez, S. Villatoro; Acosta, M. Gonzalez; Planas, C. Fina; Hierro, C.; Martin, M. Gil; Lazaro, C.; Martin-Liberal, J.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

ESMO OPEN

IF8.3

2022-10-01

OAAI

Simonelli, M.; Garralda, E.; Eskens, F.; Gil-Martin, M.; Yen, C-J; Obermannova, R.; Chao, Y.; Lonardi, S.; Melichar, B.; Moreno, V; Yu, M-L; Bongiovanni, A.; Calvo, E.; Rottey, S.; Machiels, J-P; Gonzalez-Martin, A.; Paz-Ares, L.; Chang, C-L; Mason, W.; Lin, C-C; Reardon, D. A.; Vieito, M.; Santoro, A.; Meng, R.; Abbadessa, G.; Menas, F.; Lee, H.; Liu, Q.; Combeau, C.; Ternes, N.; Ziti-Ljajic, S.; Massard, C.

(EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study

ANNALS OF ONCOLOGY

IF65.4

2022-09-01

OAAI

Reardon, D. A.; Idbaih, A.; Vieito Villar, M.; Tabatabai, G.; Stradella, A.; Ghiringhelli, F.; Burger, M.; Gonzalez Rodriguez, M.; Hervieu, A.; Mildenberger, I.; Gil Martin, M.; Renovanz, M.; Touat, M.; Wen, P.; Wick, A.; Gouttefangeas, C.; Maia, A.; Bonny, C.; Fagerberg, J.; Wick, W.

Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model

ANNALS OF ONCOLOGY

IF65.4

2022-09-01

OAAI

Perez Fidalgo, J. A.; Martinez Pretel, J. J.; Heredia, V.; Romeo Marin, M.; Mendiola, M.; Hochstadt, J.; Bernat, A.; Sanchez-Serrano, P.; Redondo Sanchez, A.; Gil Martin, M.; Guerra Ojeda, S.; Teruel, I.; Burgues, O.; Cervantes, A.; Pineda Merlo, B.

研究方向